Hi @gaurav_681, the company recently completed a slump sale of its API and CRAMS business to Synthimed Labs for ₹1,650 crore on March 18, 2024 , allowing it to reduce debt completely and concentrate on higher-margin formulation products. By selling this segment, the Company paid off almost all of its loan and NCD. So now as on 31 March 2024, the Company is very light on debt and have huge cash reserve for further expansion in formulation business. The book value as on 31 March 2024 is INR 158. It indicates that it is trading at lower price of its genuine book value. Hence good margin of safety is available for all investors in this stock. Seems to be good bet for further any kind of business growth in this Company.
Posts tagged Value Pickr
Research on Ind Swift Laboratories Ltd (21-08-2024)
Hi @gaurav_681, the company recently completed a slump sale of its API and CRAMS business to Synthimed Labs for ₹1,650 crore on March 18, 2024 , allowing it to reduce debt completely and concentrate on higher-margin formulation products. By selling this segment, the Company paid off almost all of its loan and NCD. So now as on 31 March 2024, the Company is very light on debt and have huge cash reserve for further expansion in formulation business. The book value as on 31 March 2024 is INR 158. It indicates that it is trading at lower price of its genuine book value. Hence good margin of safety is available for all investors in this stock. Seems to be good bet for further any kind of business growth in this Company.
Va Tech Wabag (21-08-2024)
Be mindful of elongating WC cycle, Trade receivables are 70% of revenue for FY24. So cash generation is slow.
Va Tech Wabag (21-08-2024)
Be mindful of elongating WC cycle, Trade receivables are 70% of revenue for FY24. So cash generation is slow.
Gufic BioSciences Ltd (21-08-2024)
Company’s profit is the same for the last 12 quarters. 12 quarters is 3 years.
Imagine no profit growth for 3 years. Despite this it admirable to see your confidence in the company.
The question one needs to ask is, “Is it possible the company is misleading investors about the future like they have been doing for 3 years?”
Gufic BioSciences Ltd (21-08-2024)
Company’s profit is the same for the last 12 quarters. 12 quarters is 3 years.
Imagine no profit growth for 3 years. Despite this it admirable to see your confidence in the company.
The question one needs to ask is, “Is it possible the company is misleading investors about the future like they have been doing for 3 years?”